Results of the Activ8 trial of novel immunotherapy motolimod

Share :
Published: 10 Oct 2016
Views: 2117
Dr Ezra Cohen - UC San Diego, San Diego, USA

Dr Cohen speaks with ecancertv at ESMO 2016 about the Activ8 trial, which sought to combine cetuximab and chemotherapy with toll-like-receptor agonist motolimod.

He describes the pathways by which motolimod redirects CD8 T cells towards non-immunogenic tumours, though reports the Activ8 trial as a statistically negative trial having not met its end-points.

Thought a negative trial in this instance, he describes the immune activity in a subset of patients who responded best as indicative of motolimods potential for future trials.